No Data
No Data
Morgan Stanley Initiates PROCEPT BioRobotics(PRCT.US) With Buy Rating, Announces Target Price $105
PROCEPT BioRobotics: Strong Market Positioning and Growth Potential With Aquablation Technology and Hydros System
Procept BioRobotics Initiated With an Overweight at Morgan Stanley
Leerink Partners Sticks to Their Buy Rating for PROCEPT BioRobotics (PRCT)
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
Express News | Procept Biorobotics Corp : Leerink Partners Cuts Target Price to $102 From $103
No Data
No Data
Yolo_tdm : thank u
Stock_Drift OP Yolo_tdm : YW. Appreciate it.
105711459 : Appreciate it, crazy performance by $Healthcare Triangle (HCTI.US)$
Boxman Stock_Drift OP : Nice volume here
Stock_Drift OP Boxman : Unusually nice.
View more comments...